Close Menu

SureGene

This article has been updated to include information about a competing product in the market.

The pharmacy benefits manager will study whether its members are more willing to take -- and stick with -- antidepressant and antipsychotic drugs prescribed to them based on a genetic test that suggests they are most likely to benefit from such treatment.

The company has received a $224,500 Therapeutic Discovery Project Tax Credit and a $365,579 SBIR Phase II matching grant from the Commonwealth of Kentucky to continue the development of a predictive test to guide treatment of antipsychotic drugs.

The alliance aims to validate whether polymorphisms identified by SureGene in the SULT4A1 gene can be used to stratify best responders to the four most widely prescribed atypical antipsychotics.

The two firms will study whether genetic variations can help predict response to widely prescribed antipsychotic drugs.

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.